104 related articles for article (PubMed ID: 22931672)
1. [Clinical study of intravenous injecting itraconazole as empirical antifungal therapy for patients with hematological malignancies].
Luo CW; DU X; Guo R; Weng JY; Lu ZS; Wu SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1000-4. PubMed ID: 22931672
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.
Ohta K; Nishiki Kosaka S; Nakao Y; Kumura T; Hagihara K; Sakamoto E; Okamoto S; Hirose A; Aoyama Y; Yamamura R; Hayashi Y; Umemoto Y; Terada Y; Takeoka Y; Nakane T; Koh H; Hino M
Int J Hematol; 2009 Jun; 89(5):649-55. PubMed ID: 19449195
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS; Cheong JW; Kim YK; Park J; Mun YC; Kang HJ; Yi HG; Lee JH; Kim YS; Ryoo HM; Kim SH; Kim HY; Kim JY; Lee DG; Kim HG; Kim H; Joo YD; Min YH
Ann Hematol; 2014 Jan; 93(1):33-42. PubMed ID: 23807252
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole for invasive fungal infection with pediatric malignancies.
Kobayashi R; Suzuki D; Yasuda K; Kobayashi K
Pediatr Int; 2010 Oct; 52(5):707-10. PubMed ID: 20337979
[TBL] [Abstract][Full Text] [Related]
7. [Sequential intravenous and oral itraconazole in treatment of invasive fungal infection in hematological diseases].
; Chen Y; Shen ZX
Zhonghua Nei Ke Za Zhi; 2008 Dec; 47(12):1026-9. PubMed ID: 19134310
[TBL] [Abstract][Full Text] [Related]
8. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Min WS; Shin WS
Korean J Intern Med; 2006 Sep; 21(3):165-72. PubMed ID: 17017665
[TBL] [Abstract][Full Text] [Related]
9. [Significance of monitoring trough plasma concentration levels for invasive fungal infection prophylaxis with itraconazole oral solution in patients with hematological malignancies: a prospective study].
Kawano I; Matsumoto K; Jiromaru T; Jinnochi F; Semba Y; Sugio T; Sakamoto K; Saito N; Yoshida S; Henzan H; Takase K; Morita K; Eto T
Rinsho Ketsueki; 2016; 57(12):2475-2480. PubMed ID: 28090013
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective study of efficacy and safety of itraconazole for treatment of invasive fungal infection in hematologic diseases].
Ji Y; Huang XJ
Zhonghua Nei Ke Za Zhi; 2008 Dec; 47(12):1022-5. PubMed ID: 19134309
[TBL] [Abstract][Full Text] [Related]
12. Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.
Kim SJ; Cheong JW; Min YH; Choi YJ; Lee DG; Lee JH; Yang DH; Lee SM; Kim SH; Kim YS; Kwak JY; Park J; Kim JY; Kim HG; Kim BS; Ryoo HM; Jang JH; Kim MK; Kang HJ; Cho IS; Mun YC; Jo DY; Kim HY; Park BB; Kim JS
J Korean Med Sci; 2014 Jan; 29(1):61-8. PubMed ID: 24431907
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial.
Saito AM; Yoshida I; Tanaka S; Sawamura M; Hidaka M; Yoshida S; Uike N; Kaneko Y; Miyazaki Y; Nagai H
Kurume Med J; 2021 Dec; 66(4):239-246. PubMed ID: 34544939
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of intravenous itraconazole in different antifungal strategies for patients undergoing intensive chemotherapy or hematopoietic stem cell transplantation].
Ji Y; Xu L; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):689-93. PubMed ID: 25152113
[TBL] [Abstract][Full Text] [Related]
15. [Itraconazole capsules as antifungal prophylaxis for neutropenic patients with hematological malignancies from a single institution].
Toubai T; Tanaka J; Ota S; Kato N; Umehara S; Kahata K; Toyoshima N; Asaka M; Imamura M
Jpn J Antibiot; 2005 Dec; 58(6):507-17. PubMed ID: 16521343
[TBL] [Abstract][Full Text] [Related]
16. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever.
Yoshida I; Saito AM; Tanaka S; Choi I; Hidaka M; Miyata Y; Inoue Y; Yamasaki S; Kagoo T; Iida H; Niimi H; Komeno T; Yoshida C; Tajima F; Yamamoto H; Takase K; Ueno H; Shimomura T; Sakai T; Nakashima Y; Yoshida C; Kubonishi S; Sunami K; Yoshida S; Sakurai A; Kaneko Y; Miyazaki Y; Nagai H
Mycoses; 2020 Aug; 63(8):794-801. PubMed ID: 32391919
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit].
; Qui HB
Zhonghua Nei Ke Za Zhi; 2008 Dec; 47(12):1012-6. PubMed ID: 19134307
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.
Kim JS; Cheong JW; Shin HJ; Lee JW; Lee JH; Yang DH; Lee WS; Kim H; Park JS; Kim SH; Kim YS; Kwak JY; Chae YS; Park J; Do YR; Min YH
Yonsei Med J; 2014 Jan; 55(1):9-18. PubMed ID: 24339281
[TBL] [Abstract][Full Text] [Related]
19. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
20. [An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis].
Tomioka H; Kaneda T; Kida Y; Kaneko M; Fujii H; Hayashi M; Tomii K; Tada K; Suzuki Y; Karino T
Kansenshogaku Zasshi; 2011 Nov; 85(6):644-51. PubMed ID: 22250455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
